Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441111 | 0.97 | — | — | |
| SCHEMBL2441109 | 0.97 | — | — | |
| SCHEMBL28011344 | 0.94 | TP53 (0.38) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL468405 | 0.94 | TP53 (0.38) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29098220 | 0.94 | TP53 (0.38) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL23829842 | 0.78 | TP53 (0.38) | TP53SLC7A5 | |
| SCHEMBL27867091 | 0.78 | TP53 (0.38) | TP53SLC7A5 | |
| SCHEMBL13817462 | 0.78 | — | — | |
| SCHEMBL1923464 | 0.77 | TP53 (0.42) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1923463 | 0.77 | TP53 (0.42) | TP53SLC7A5SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| CN-121248402-B | Preparation method of sodium ketovaline | 浙江昂利泰制药有限公司 | 2026-04-17 | — | — | CN | disclosed |
| CN-121248402-A | Preparation method of sodium ketovaline | 浙江昂利泰制药有限公司 | 2026-01-02 | — | — | CN | disclosed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3006023-B1 | SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151301-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10149845-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-12-11 | — | — | US | disclosed |
| US-10039730-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170189358-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-07-06 | — | — | US | disclosed |
| EP-2389187-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8040867-B2 | Method of multi-antenna wireless data emission, emitter and receiver using the method | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010085452-A9 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR - UCLA MEDICAL CENTER (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100189818-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085452-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR - UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1412515-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | Genset (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | TP53 4743/4885SLC7A5 262/4885SLC1A3 46/4885 |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | TP53 4743/4885SLC7A5 262/4885SLC1A3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.